Good morning. Three of the vendors we track moved GHK-Cu pricing down this week, and the spread between the cheapest and most expensive per-mg listing is now the tightest it has been since we started watching this compound. Here is what changed and what it means.
The movement
Two US-domestic vendors and one international vendor cut their GHK-Cu listings between Monday and Thursday. None announced it. We caught it because we re-run the per-mg math on the most-tracked compounds every week.
The practical effect: the per-mg range on a 50 mg vial compressed from a 31% spread down to a 16% spread. When the spread tightens like this, the "best deal" stops being obvious, and the right move is almost always to check the live calculator rather than rely on a vendor you trusted last month.
When the per-mg spread compresses, brand loyalty quietly starts costing you money.
Why it happened
Our read is that this is a wholesale-layer story, not a retail promotion. When several unrelated vendors move the same direction in the same week without a sale banner, the cause is usually upstream — a shift in what the active ingredient costs the vendors themselves.
One paper worth your weekend
A new dermatology review summarized the topical-versus-injectable GHK-Cu evidence in a way that is unusually honest about what the literature does and does not support. If you have been curious about the "skin one," it is a good, sober read.
That's it for this week. Reply if you spot a price move we missed — readers catch things we don't.